Ukr.Biochem.J. 2013; Volume 85, Issue 3, May-Jun, pp. 85-89


Influence of ademol on NO metabolism indices in rats with modeling myocardial infarction

O. A. Khodakovskiy1, S. V. Pavlov2, N. V. Buchtiyarova2

1Vinnitsa National Pirogov Memorial Medical University, Ukraine;
2Zaporizhzhia State Medical University, Ukraine;

It was established in experiments on the rats in the acute period of modeling pituitrin-isadrin myocardial infarction the formation of nitrogen monoxide decreases along with its accelerated transformation into peroxynitrite. It was evidenced by more than double inhibition of NO synthase activity in the myocardium and by decreasing the amount of nitrates on the background of the increasing level of peroxynitrites’ marker – nitrotyrosine by 246.6% at an average. Experimental therapy of rats by ademol which is a derivate of adamantan (1-adamantiloxy-3-morpholino-2 propanol hydrochloride) better than by corvitin normalizes the processes of synthesis of nitric oxide. At the same time ademol probably exceeded the reference drug in ability to increase NO synthase activity and amount of nitrate, and promoted a decrease of the level of nitrotyrosine in the myocardium on the average by 36.3; 50.6 and 12.7%, respectively. Corrective influence of ademol on indicators of metabolism in NO system under the conditions of acute cardiac ischemia indicates to promicing development of domestic cardioprotector on its base.

Keywords: , , ,


  1. Tseluyko VI, Mishchuk NE. Diagnosis and treatment of complications of myocardial infarction. Liky Ukrainy. 2009;(4):33-39.
  2. Lapshina LA, Kravchun PG, Titova AY, Glebova OV. The importance of nitrates and nitrites’ content estimation, as markers of endothelial dysfunction in cardiovascular pathology. Ukr Med J. 2009;11–12(6(74)):49-53.
  3. Adlbrecht C, Andreas M, Redwan B, Distelmaier K, Beran G,  Kaider A. Reduction of enzymatic infarct size by endothelin receptor blockade in acute ST-segment elevation myocardial infarction. Eur Heart J. 2010;31:892.
  4. Voloshin P.V., Malakho V.A., Zavgorodniaya A.N. Endothelial dysfunction in cerebrovascular desease. Kharkov, 2006. 92 p.
  5. Stoclet J-C, Muller B,  Andriantsitohaina R, Kleschyov A.  Overproduction of Nitric Oxide in Pathophysiology of Blood Vessels. Biochemistry (Mosc). 1998 Jul;63(7):826-32. PubMed
  6. Markov HM. Nitrogen oxide and the cardiovascular system.  Usp Fiziol Nauk. 2001 Jul-Sep;32(3):49-65. Review. Russian.  PubMed
  7. Sahach VF, Andrukhov OYa. The effect of nitric oxide on the contractile activity of skinned preparations of the smooth muscles of the rat portal vein. Fiziol Zhurn. 2000;46(1):3-9. Ukrainian. PubMed
  8. Champion HC, Georgakopoulos D, Takimoto E, Isoda T, Wang Y, Kass DA. Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3. Circ Res. 2004 Mar 19;94(5):657-63. PubMed, CrossRef
  9. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002 Jan 10;415(6868):198-205. Review. PubMed, CrossRef
  10. Okhotin VE, Shuklin AV. Significance of neuronal, endothelial and inducible NO-synthase isoforms in the cardiac muscle histophysiology. Morfologiia. 2006;129(1):7-17. Russian. PubMed
  11. Moybenko AA, Pavlyuchenko VB, Datsenko VV, Maisky VA. Role of Nitric Oxide in the Mechanisms of Formation of Reflex Vasomotor Responses. Usp Fiziol Nauk. 2005 Oct-Dec;36(4):3-12. PubMed
  12. Rakhmatullina FF, Chelyshev YuA, Zefirov AL. Morphological and functional alterations in  rat ischemized myocardium upon the changes in nitrogen oxide content. Ross Fiziol Zh Im I M Sechenova. 2004 Aug;90(8):449.
  13. Danson EJ, Paterson DJ. Cardiac neurobiology of nitric oxide synthases. Ann N Y Acad Sci. 2005 Jun;1047(1):183-96. Review. PubMed, CrossRef
  14. Datsenko VV, Pavliuchenko VB, Moibenko AA. Role of the nitric oxide system in the realization of cardiogenic and sinocarotid reflexes. Arch Clin Exp Med. 2003;12(1):8-9.
  15. Kurhaliuk NM, Serebrovs’ka TV, Nosar VI, Kolesnikova EE, Moybenko OO. Intermittent hypoxic training and L-arginine as corrective agents for myocardial energy supply under acute hypoxia. Ukr Biokhim Zhurn. 2002 Jan-Feb;74(1):82-7. Ukrainian. PubMed
  16. Belenichev I, Kucherenko L, Bukhtiyarova N, Steblyuk V, Pavlyuk I, Portnaya E. Pharmacological correction of violations in conjugated systems NO – free thiols by metabolitotropic cardioprotector “liziniy” in experimental myocardial infarction. Exp Clin Physiol Biochem. 2012;(2(58)):7-11.
  17. Reutov VP, Gozhenko AI, Okhotin VE, Kotuzhinskaya SG, Shuklin AV, Sorokina EG. Role of nitrogen oxide in myocardium work adjusting/cycle of nitrogen oxide and NO/synthetase systems in myocardium. Actual Probl Transp Med.  2007;(4(10)):89-112.
  18. Troshin VD, Brovkov NN. Emergency kardionevrologiya. M.: Acad.MIA. 2010; 672p.
  19. Moibenko AA, Dosenko VE, Parkhomenko AN. Endogenous mechanisms of cardioprotection as the basis of pathogenetic therapy of heart diseases. K.: Naukova dumka. 2008. 514p.
  20. Moibenko AA, Dosenko VE, Parkhomenko AN.  The problem of the pathogenesis and endoprotektsii in acute ischemia and myocardial infarction. Visnik Farmacii. 2008;(9):56-61.
  21. Privalov DV, Intravenous application of  nitroglycerin in emergency cardiology. Emergency Medicin. 2010;(1(26)):24-27.
  22. Moibenko AA, Pathogenetic study of the efficiency of new domestic cardioprotector Сorvitin (water-soluble quercetin) in acute myocardial infarction. Visnik Farmacii. 2007;(5):38-47.
  23. Lonska OP, Study of hepatoprotective activity of new adamantane derivatives. Avtoref. dis. …. kand. med. nauk, Odesa, 2008. 19 p.
  24. Khodakovskiy OA, Study of the protective effect  of new adamantane derivatives on  myocardium upon experimental cardiogenic shock. Reports Morphol. 2010;16(3):564-568.
  25. Khodakovskiy OA,  Study of the Ademol (compound code UK-1) effect on the coronary and systemic hemodynamics under anesthesia. Biomed Biosoc Anthropol. 2011;(16):7-9.
  26. Chekman IS, Kolesnik YuM, Mazur IA, Belenichev IF, AbramovbAV, Kucherenko LI, Pavlov SV, Bukhtiyarova NV, Gorchakova NA, Some aspects of the cardio protective effect of prospective anti-anginal drug “MT” upon the modeling of acute myocardial ischemia. Zaporozh Med Zhurn. 2010;12(5):198-201.
  27. Korenman NM, Methods for the determination of organic compounds. M.: Khimiya. 1975: 360 p.
  28. Chekman IS, Gubskiy YuI, Gromov LA, Belenichev IF, Preclinical study of specific activity of potential neuroprotective preparations. Guidelines of State Pharmacological Center of the Ministry of Health of Ukraine. Kiev; 2010: 81 p.
  29. Reutov VP. Nitric oxide cycle in mammals and the cyclicity principle. Biochemistry (Mosc). 2002 Mar;67(3):293-311. Review. PubMed, CrossRef
  30. Gödecke A, Molojavyi A, Heger J, Flögel U, Ding Z, Jacoby C, Schrader J. Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress. J Biol Chem. 2003 Jun 13;278(24):21761-6. PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.